Why Jim Cramer Is Bullish on Merck

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Merck's (MRK) - Get Report stock. Shares surged on Thursday following upbeat results on its lung cancer treatment study. The trial found that the drug, KEYTRUDA, was more effective than chemotherapy. 'We believe that the KEYNOTE-024 results have the potential to change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer,' said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. Cramer pointed to TheStreet's Adam Feuerstein who has been covering the developments.

At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.